Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125258261 | 12525826 | 1 | I | 2011 | 20160419 | 20160705 | 20160705 | PER | US-ASTRAZENECA-2016SE42246 | ASTRAZENECA | 67.00 | YR | M | Y | 92.50000 | KG | 20160705 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125258261 | 12525826 | 1 | PS | BYETTA | EXENATIDE | 1 | Subcutaneous | Y | 21773 | 5 | UG | SOLUTION FOR INJECTION IN PRE-FILLED PEN | BID | ||||||
| 125258261 | 12525826 | 2 | SS | BYETTA | EXENATIDE | 1 | Subcutaneous | Y | 21773 | 5 | UG | SOLUTION FOR INJECTION IN PRE-FILLED PEN | BID | ||||||
| 125258261 | 12525826 | 3 | SS | BYDUREON | EXENATIDE | 1 | Subcutaneous | U | 0 | 2 | MG | /wk | |||||||
| 125258261 | 12525826 | 4 | SS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | 0 | 40 | MG | QD | ||||||||
| 125258261 | 12525826 | 5 | C | ACTOS | PIOGLITAZONE HYDROCHLORIDE | 1 | Oral | 0 | 45 | MG | QD | ||||||||
| 125258261 | 12525826 | 6 | C | COZAAR | LOSARTAN POTASSIUM | 1 | Oral | 0 | 100 | MG | BID | ||||||||
| 125258261 | 12525826 | 7 | C | VYTORIN | EZETIMIBESIMVASTATIN | 1 | Oral | 0 | 40 | MG | QD | ||||||||
| 125258261 | 12525826 | 8 | C | PLAVIX | CLOPIDOGREL BISULFATE | 1 | Oral | 0 | 75 | MG | QD | ||||||||
| 125258261 | 12525826 | 9 | C | COREG | CARVEDILOL | 1 | Oral | 0 | 6.25 | MG | BID | ||||||||
| 125258261 | 12525826 | 10 | C | GLUCATROL | 2 | Oral | 0 | 5 | MG | BID | |||||||||
| 125258261 | 12525826 | 11 | C | WELLBUTRIN | BUPROPION HYDROCHLORIDE | 1 | Oral | 0 | 150 | MG | BID | ||||||||
| 125258261 | 12525826 | 12 | C | WELLBUTRIN | BUPROPION HYDROCHLORIDE | 1 | Oral | 0 | 150 | MG | BID | ||||||||
| 125258261 | 12525826 | 13 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Oral | 0 | 1500 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125258261 | 12525826 | 1 | Type 2 diabetes mellitus |
| 125258261 | 12525826 | 2 | Type 2 diabetes mellitus |
| 125258261 | 12525826 | 3 | Type 2 diabetes mellitus |
| 125258261 | 12525826 | 4 | Gastrooesophageal reflux disease |
| 125258261 | 12525826 | 5 | Diabetes mellitus |
| 125258261 | 12525826 | 6 | Hypertension |
| 125258261 | 12525826 | 7 | Blood cholesterol abnormal |
| 125258261 | 12525826 | 9 | Cardiac disorder |
| 125258261 | 12525826 | 10 | Diabetes mellitus |
| 125258261 | 12525826 | 11 | Depression |
| 125258261 | 12525826 | 12 | Smoking cessation therapy |
| 125258261 | 12525826 | 13 | Diabetes mellitus |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125258261 | 12525826 | Gastrooesophageal reflux disease | |
| 125258261 | 12525826 | Injection site nodule | |
| 125258261 | 12525826 | Injection site pain | |
| 125258261 | 12525826 | Nephrolithiasis | |
| 125258261 | 12525826 | Underdose |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125258261 | 12525826 | 1 | 1990 | 0 | ||
| 125258261 | 12525826 | 2 | 201601 | 0 | ||
| 125258261 | 12525826 | 3 | 201601 | 0 | ||
| 125258261 | 12525826 | 4 | 2014 | 0 | ||
| 125258261 | 12525826 | 8 | 2006 | 0 |